Immix Biopharma, Inc. (IMMX) Balance Sheet
IMMX balance sheet, 2025
December 31, 2025 · U.S. dollars$104.8M assets = $11.0M liabilities + $93.8M equity
Both columns are drawn to the same scale: what IMMX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
IMMX financial health
Descriptive bands, not a rating. Fiscal 2025.
IMMX balance sheet trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $942,9442019 | $104.8M2025 | +119.3%/yr | |
| Total liabilities | $4.6M2019 | $11.0M2025 | +15.8%/yr | |
| Shareholders’ equity | −$3.6M2019 | $93.8M2025 | — | |
| Cash & short-term investments | $734,0142019 | $100.4M2025 | +127.0%/yr | |
| Total debt | $4.1M2019 | $1.1M2025 | −20.0%/yr | |
| Net cash (debt) | −$3.4M2019 | $99.3M2025 | +$102.7M | |
| Working capital | −$3.7M2019 | $91.1M2025 | +$94.8M | |
| Book value per share | $0.952023 | $2.852025 | +73.4%/yr | |
| Debt / equity | 0.002021 | 0.012025 | +0.01 | |
| Shares outstanding | 17.3M2023 | 33.0M2025 | +37.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IMMX assets
IMMX liabilities and equity
IMMX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
IMMX balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $100.4M | $17.7M | $17.5M | $13.4M | $17.6M | $391,086 | $734,014 |
| Cash & equivalents | $93.9M | $17.7M | $17.5M | $13.4M | $17.6M | $391,086 | $734,014 |
| Short-term investments | $6.5M | $0 | — | — | — | — | — |
| Receivables | $0 | $2.0M | $1.2M | $255,705 | $25,722 | $127,436 | $175,748 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $828,329 | $541,510 | $1.1M | $1.2M | $516,193 | $13,714 | $23,500 |
| Total current assets | $101.2M | $20.2M | $19.8M | $14.9M | $18.2M | $532,236 | $933,262 |
| Property, plant & equipment (net) | $3.5M | $2.7M | $50,181 | $3,560 | $5,695 | $7,361 | $9,682 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $114,048 | $20,418 | $87,229 | $6,724 | $0 | $0 | $0 |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M | $539,597 | $942,944 |
| Liabilities | |||||||
| Accounts payable | $5.4M | $5.4M | $1.4M | $143,074 | $142,940 | $252,344 | $247,542 |
| Short-term debt | $139,339 | $65,219 | — | — | $50,000 | $4.1M | $4.1M |
| Deferred revenue | — | — | — | — | — | $342,837 | — |
| Total current liabilities | $10.1M | $8.7M | $3.7M | $1.3M | $202,039 | $5.3M | $4.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $1.1M | $1.1M | $0 | — | — | — | — |
| Other long-term liabilities | $933,625 | $1.0M | $0 | $475,000 | $192,940 | $4.4M | $4.3M |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202,039 | $5.3M | $4.6M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $5,301 | $2,762 | $2,000 | $1,397 | $1,323 | $338 | $338 |
| Retained earnings (deficit) | −$104.5M | −$75.0M | −$53.4M | −$38.0M | −$29.8M | −$5.4M | −$4.2M |
| Accumulated other comprehensive income | $60,160 | −$1,056 | $134,666 | $87,021 | $125,408 | $131,861 | $68,224 |
| Minority interest | $0 | $0 | −$201,737 | $0 | — | — | — |
| Total shareholders' equity | $93.8M | $13.3M | $16.4M | $13.2M | $18.0M | −$4.7M | −$3.6M |
| Key figures | |||||||
| Total debt | $1.1M | $1.1M | — | — | $50,000 | $4.1M | $4.1M |
| Net cash (debt) | $99.3M | $16.6M | — | — | $17.6M | −$3.7M | −$3.4M |
| Working capital | $91.1M | $11.5M | $16.1M | $13.6M | $18.0M | −$4.7M | −$3.7M |
| Tangible book value | $93.8M | $13.3M | $16.4M | $13.2M | $18.0M | −$4.7M | −$3.6M |
| Book value per share | $2.85 | $0.47 | $0.95 | — | — | — | — |
| Shares outstanding | 33.0M | 28.3M | 17.3M | — | — | — | — |
| Current ratio | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 | 0.10 | 0.20 |
| Quick ratio | 9.93 | 2.26 | 5.02 | 10.75 | 87.46 | 0.10 | 0.20 |
| Debt / equity | 0.01 | 0.08 | — | — | 0.00 | — | — |
| Equity / assets | 89.5% | 57.7% | 82.3% | 88.3% | 98.9% | −876.7% | −386.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $232.1M | $90.6M | $100.4M | $15.9M | $11.6M | $15.9M | $17.7M | $19.7M | $24.0M | $29.3M | $17.5M | $19.6M |
| Cash & equivalents | $225.5M | $79.3M | $93.9M | $15.9M | $11.6M | $15.9M | $17.7M | $19.7M | $24.0M | $29.3M | $17.5M | $19.6M |
| Short-term investments | $6.6M | $11.3M | $6.5M | — | — | — | $0 | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $2.0M | $2.0M | $2.0M | $2.0M | $1.2M | $652,482 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 | $0 | $0 |
| Other current assets | $1.7M | $1.7M | $828,329 | $636,972 | $687,515 | $858,143 | $541,510 | $1.1M | $1.4M | $1.6M | $1.1M | $2.1M |
| Total current assets | $233.8M | $92.3M | $101.2M | $16.6M | $12.3M | $16.8M | $20.2M | $22.8M | $27.3M | $32.9M | $19.8M | $22.3M |
| Property, plant & equipment (net) | $3.2M | $3.4M | $3.5M | $3.4M | $3.2M | $3.1M | $2.7M | $2.4M | $1.5M | $1.4M | $50,181 | $40,080 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $2.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $20,418 | $185,141 | $114,048 | $132,107 | $131,024 | $20,418 | $20,418 | $20,418 | $20,418 | $20,418 | $87,229 | $103,191 |
| Total assets | $239.1M | $95.8M | $104.8M | $20.1M | $15.6M | $19.9M | $22.9M | $25.1M | $28.8M | $34.3M | $19.9M | $22.5M |
| Liabilities | ||||||||||||
| Accounts payable | $5.3M | $4.7M | $5.4M | $7.1M | $6.6M | $5.7M | $5.4M | $3.3M | $2.3M | $3.5M | $1.4M | $1.6M |
| Short-term debt | $111,114 | $125,392 | $139,339 | $141,282 | $70,467 | $67,817 | $65,219 | $62,715 | $48,359 | $34,284 | — | — |
| Deferred revenue | — | — | — | — | — | — | — | — | −$48,359 | — | — | — |
| Total current liabilities | $9.3M | $10.5M | $10.1M | $10.9M | $10.0M | $9.3M | $8.7M | $6.6M | $3.9M | $5.7M | $3.7M | $2.8M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $1.0M | $1.0M | $1.1M | $1.1M | $1.0M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $0 | — |
| Other long-term liabilities | $890,638 | $912,343 | $933,625 | $965,053 | $972,335 | $991,126 | $1.0M | $1.0M | $1.0M | $1.1M | $0 | $0 |
| Total liabilities | $10.2M | $11.5M | $11.0M | $11.8M | $11.0M | $10.3M | $9.7M | $7.6M | $4.9M | $6.7M | $3.7M | $2.8M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $7,160 | $5,307 | $5,301 | $3,311 | $2,847 | $2,793 | $2,762 | $2,757 | $2,752 | $2,648 | $2,000 | $1,968 |
| Retained earnings (deficit) | −$126.1M | −$114.5M | −$104.5M | −$93.8M | −$86.2M | −$79.6M | −$75.0M | −$70.2M | −$63.1M | −$58.7M | −$53.4M | −$48.3M |
| Accumulated other comprehensive income | $118,720 | $105,636 | $60,160 | $62,464 | $65,032 | $15,463 | −$1,056 | $192,051 | $116,972 | $89,614 | $134,666 | $46,735 |
| Minority interest | — | — | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Total shareholders' equity | $228.9M | $84.4M | $93.8M | $8.3M | $4.7M | $9.6M | $13.3M | $17.6M | $23.9M | $27.9M | $16.4M | $19.8M |
| Key figures | ||||||||||||
| Total debt | $1.0M | $1.0M | $1.1M | $1.1M | $1.0M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | — | — |
| Net cash (debt) | $231.1M | $89.5M | $99.3M | $14.8M | $10.6M | $14.9M | $16.6M | $18.6M | $22.9M | $28.2M | — | — |
| Working capital | $224.5M | $81.7M | $91.1M | $5.7M | $2.3M | $7.5M | $11.5M | $16.2M | $23.4M | $27.3M | $16.1M | $19.5M |
| Tangible book value | $228.9M | $84.4M | $93.8M | $8.3M | $4.7M | $9.6M | $13.3M | $17.6M | $23.9M | $27.9M | $16.4M | $19.8M |
| Book value per share | $3.59 | $1.52 | $2.45 | $0.26 | $0.16 | $0.32 | $0.48 | $0.60 | $0.83 | $1.19 | $0.82 | $1.06 |
| Shares outstanding | 63.8M | 55.4M | 38.3M | 31.9M | 30.0M | 29.7M | 27.5M | 29.4M | 28.8M | 23.4M | 19.9M | 18.6M |
| Current ratio | 25.13 | 8.76 | 10.01 | 1.53 | 1.23 | 1.80 | 2.33 | 3.47 | 7.00 | 5.82 | 5.32 | 7.90 |
| Quick ratio | 24.95 | 8.59 | 9.93 | 1.47 | 1.16 | 1.71 | 2.26 | 3.30 | 6.65 | 5.54 | 5.02 | 7.16 |
| Debt / equity | 0.00 | 0.01 | 0.01 | 0.13 | 0.22 | 0.11 | 0.08 | 0.06 | 0.05 | 0.04 | — | — |
| Equity / assets | 95.7% | 88.0% | 89.5% | 41.2% | 29.8% | 48.2% | 57.7% | 69.8% | 82.9% | 81.3% | 82.3% | 88.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 25, 2026); data from EODHD.
IMMX financial position
At the end of fiscal 2025 (December 31, 2025), Immix Biopharma had total assets of $104.8 million (up 356.9% from a year earlier), total liabilities of $11.0 million and shareholders' equity of $93.8 million. It held $100.4 million in cash and short-term investments against $1.1 million of debt, a net cash position of $99.3 million. Its current ratio was 10.01. In the latest quarter (ended June 30, 2026) total assets were $239.1 million and equity $228.9 million.
Related: IMMX income statement, IMMX cash flow statement, IMMX key metrics. See the IMMX stock overview for the latest quote and news.
IMMX balance sheet FAQ
What are Immix Biopharma's total assets?
Immix Biopharma reported total assets of $104.8 million at the end of fiscal 2025 (December 31, 2025), compared with $22.9 million a year earlier.
How much debt does Immix Biopharma have?
Immix Biopharma had $1.1 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.01.
How much cash does Immix Biopharma have?
Immix Biopharma held $100.4 million in cash and short-term investments at the end of fiscal 2025; with $1.1 million of debt that is net cash of $99.3 million.
What is Immix Biopharma's book value?
Immix Biopharma's shareholders' equity (book value) was $93.8 million at the end of fiscal 2025, or $2.85 per share.
What is Immix Biopharma's current ratio?
Immix Biopharma had current assets of $101.2 million and current liabilities of $10.1 million, a current ratio of 10.01 (it can cover its short-term obligations).